Sign in
SNDX Stock Price, Chart, Stats & News
Syndax Pharmaceuticals, Inc.
Save
1.68B
Market cap
–
Current P/E
–
Forward P/E
SNDX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 95.96% |
Operating margin | -158.45% |
Pretax margin | -165.60% |
Net margin | -165.60% |
Effective tax rate | – |
ROA | -53.88% |
ROE | -206.62% |
D/E | 5.36x |
Interest coverage ratio | -3.81x |
SNDX valuation
P/E | – |
P/S | 12.02x |
P/B | 31.48x |
P/CF | -6.30x |
P/FCF | -6.41x |
P/OCF | -6.30x |
PEG | -0.81x |
EV multiple | -8.43x |
About
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD).
Similar securities
Based on sector and market capitalization
Report issue